CorMedix
CRMD
79 hedge funds and large institutions have $107M invested in CorMedix in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 12 closing their positions.
96% more call options, than puts
Call options by funds: $4.2M | Put options by funds: $2.14M
57% more capital invested
Capital invested by funds: $68.7M → $107M (+$38.8M)
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
5% more funds holding
Funds holding: 75 → 79 (+4)
4.74% more ownership
Funds ownership: 28.83% → 33.56% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.93M |
| 2 |
BlackRock
New York
|
+$2.72M |
| 3 |
Morgan Stanley
New York
|
+$2.57M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.41M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Elliott Investment Management
West Palm Beach,
Florida
|
-$2.19M |
| 2 |
Two Sigma Investments
New York
|
-$1.13M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$892K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$582K |
| 5 |
Two Sigma Advisers
New York
|
-$382K |
CRMD Hedge Fund Activity: Q1 2021 in Review
79 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q1 2021, worth a combined $107M — up 57% from $68.7M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CRMD positions and 12 closed out — a net gain of 4 holders — while 26 added to existing stakes and 21 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $7.93M. The largest seller was Elliott Investment Management, cutting an estimated $2.19M.
- 79 institutional investors held CorMedix (CRMD) as of Q1 2021, up from 75 in Q4 2020.
- Funds reported $107M of CorMedix stock for Q1 2021, up 57% quarter-over-quarter.
- 16 funds opened new CorMedix positions in Q1 2021 and 12 closed out, a net change of +4 holders.
- The largest CorMedix buyer in Q1 2021 was Credit Suisse, an estimated $7.93M added.
- The largest CorMedix seller in Q1 2021 was Elliott Investment Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q1 2021.